医疗外包服务

Search documents
招银国际:首予药明合联(02268)“买入”评级 目标价74港元
Zhi Tong Cai Jing· 2025-09-02 09:18
Core Viewpoint - 招银国际 has initiated coverage on WuXi AppTec (02268) with a "Buy" rating and a target price of HKD 74 [1] Financial Projections - The company is expected to see revenue growth of 45.7%, 35.7%, and 30.9% for the years 2025 to 2027 [1] - Adjusted net profit is projected to grow by 40%, 32.4%, and 30.8% during the same period [1] Company Positioning - WuXi AppTec has established itself as a leader in the global XDC outsourcing service industry [1] - The company offers "one-stop" XDC research and production services at its Wuxi base and is currently constructing a new facility in Singapore [1] Project Pipeline - The number of projects is rapidly increasing, with 19 Phase III clinical projects and 11 PPQ stage projects as of the first half of this year [1] - Future growth will be supported by ongoing and commercialized projects [1]